Alex Thompson
Stock Analyst at Stifel
(4.13)
# 465
Out of 5,148 analysts
44
Total ratings
63.89%
Success rate
11.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Reiterates: Buy | $58 → $68 | $30.00 | +126.67% | 1 | Feb 26, 2026 | |
| ALMS Alumis | Initiates: Buy | $44 | $29.72 | +48.05% | 1 | Feb 25, 2026 | |
| PALI Palisade Bio | Initiates: Buy | $5 | $1.81 | +176.24% | 1 | Feb 25, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $254 → $256 | $242.09 | +5.75% | 4 | Dec 11, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,028 → $1,248 | $756.76 | +64.91% | 5 | Dec 11, 2025 | |
| ANAB AnaptysBio | Maintains: Buy | $80 → $56 | $54.91 | +1.99% | 2 | Dec 11, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $55.26 | +17.63% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $29.53 | -15.34% | 4 | Sep 12, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $15.99 | +37.59% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $90.10 | -38.96% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $17.98 | +100.22% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $40.68 | +47.49% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $49 | $33.69 | +45.44% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 → $54 | $42.49 | +27.09% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $13.98 | -85.69% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $17.68 | +290.27% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $3.05 | -67.21% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $30.25 | +32.23% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $58.02 | +451.53% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $27.75 | +22.52% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.27 | +2,498.43% | 1 | Dec 14, 2022 |
Celldex Therapeutics
Feb 26, 2026
Reiterates: Buy
Price Target: $58 → $68
Current: $30.00
Upside: +126.67%
Alumis
Feb 25, 2026
Initiates: Buy
Price Target: $44
Current: $29.72
Upside: +48.05%
Palisade Bio
Feb 25, 2026
Initiates: Buy
Price Target: $5
Current: $1.81
Upside: +176.24%
Ascendis Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $254 → $256
Current: $242.09
Upside: +5.75%
argenx SE
Dec 11, 2025
Maintains: Buy
Price Target: $1,028 → $1,248
Current: $756.76
Upside: +64.91%
AnaptysBio
Dec 11, 2025
Maintains: Buy
Price Target: $80 → $56
Current: $54.91
Upside: +1.99%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $55.26
Upside: +17.63%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $29.53
Upside: -15.34%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $15.99
Upside: +37.59%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $90.10
Upside: -38.96%
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $17.98
Upside: +100.22%
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $40.68
Upside: +47.49%
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $33.69
Upside: +45.44%
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $42.49
Upside: +27.09%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $13.98
Upside: -85.69%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $17.68
Upside: +290.27%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $3.05
Upside: -67.21%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $30.25
Upside: +32.23%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $58.02
Upside: +451.53%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $27.75
Upside: +22.52%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.27
Upside: +2,498.43%